Sunil Sharma

9.5k total citations · 1 hit paper
139 papers, 3.8k citations indexed

About

Sunil Sharma is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sunil Sharma has authored 139 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Molecular Biology, 64 papers in Oncology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sunil Sharma's work include Histone Deacetylase Inhibitors Research (20 papers), Protein Degradation and Inhibitors (20 papers) and Colorectal Cancer Treatments and Studies (19 papers). Sunil Sharma is often cited by papers focused on Histone Deacetylase Inhibitors Research (20 papers), Protein Degradation and Inhibitors (20 papers) and Colorectal Cancer Treatments and Studies (19 papers). Sunil Sharma collaborates with scholars based in United States, India and Switzerland. Sunil Sharma's co-authors include Hariprasad Vankayalapati, David J. Bearss, Steven L. Warner, Kapil N. Bhalla, Arvinder Kaur, Owias Iqbal Dar, Anupam Verma, Venkataswamy Sorna, Michael S. Gordon and Emily R. Theisen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular and Cellular Biology.

In The Last Decade

Sunil Sharma

132 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

2016 661 citations Michael S. Gordon, Sunil Sharma et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sunil Sharma United States	32	1.9k	1.5k	582	556	482	139	3.8k
Andries M. Bergman Netherlands	33	1.6k 0.9×	1.8k 1.2×	1.6k 2.8×	211 0.4×	725 1.5×	158	4.5k
Pengda Liu United States	35	3.4k 1.8×	996 0.7×	471 0.8×	672 1.2×	157 0.3×	79	4.7k
Mickey C.‐T. Hu United States	33	3.2k 1.7×	1.3k 0.8×	543 0.9×	517 0.9×	174 0.4×	51	4.4k
Donatella Aldinucci Italy	40	1.5k 0.8×	2.4k 1.6×	358 0.6×	1.7k 3.1×	220 0.5×	97	5.4k
Françis Frankenne Belgium	39	1.3k 0.7×	859 0.6×	404 0.7×	782 1.4×	397 0.8×	113	5.3k
Wenhong Fan United States	31	1.6k 0.9×	547 0.4×	179 0.3×	252 0.5×	155 0.3×	69	2.8k
W. David Henner United States	43	2.9k 1.5×	1.9k 1.2×	988 1.7×	135 0.2×	322 0.7×	95	5.5k
Bernard W. Futscher United States	43	3.6k 1.9×	1.2k 0.8×	271 0.5×	187 0.3×	179 0.4×	91	4.9k
Alan O. Perantoni United States	38	2.8k 1.5×	573 0.4×	807 1.4×	168 0.3×	375 0.8×	91	4.0k
Dirk Eulberg Germany	30	1.5k 0.8×	497 0.3×	127 0.2×	880 1.6×	300 0.6×	49	3.6k

Countries citing papers authored by Sunil Sharma

Since Specialization

Citations

This map shows the geographic impact of Sunil Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Sharma more than expected).

Fields of papers citing papers by Sunil Sharma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Sharma. The network helps show where Sunil Sharma may publish in the future.

Co-authorship network of co-authors of Sunil Sharma

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Sharma. A scholar is included among the top collaborators of Sunil Sharma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Sharma. Sunil Sharma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dar, Owias Iqbal, et al.. (2024). Dynamic alterations in physiological and biochemical indicators of Cirrhinus mrigala hatchlings: A sublethal exposure of triclosan. The Science of The Total Environment. 924. 171701–171701. 4 indexed citations

Thakur, Shubham, et al.. (2024). Pre-clinical and cellular safety assessment of oral administered DHA rich microalgae oil from Schizochytrium sp. (Strain ATCC-20889): acute, sub-chronic and genotoxicity. Drug and Chemical Toxicology. 47(6). 876–888. 1 indexed citations

Li, Daneng, Hee Kyung Kim, Sun Young Kim, et al.. (2024). Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).. Journal of Clinical Oncology. 42(3_suppl). 127–127.

Sharma, Sunil, et al.. (2023). Biopreservative efficacy of Enterococcus faecium-immobilised film and its enterocin against Salmonella enterica. AMB Express. 13(1). 11–11. 5 indexed citations

Singh, Harjeet, Harmanpreet Singh, Sunil Sharma, et al.. (2023). Genotoxic and mutagenic potential of 7-methylxanthine: an investigational drug molecule for the treatment of myopia. Drug and Chemical Toxicology. 47(3). 264–273. 7 indexed citations

Sharma, Sunil, et al.. (2023). Public Library Services in Digital Environment: A study on Innovation activities with special reference to Public Libraries in Rajasthan. 43(2). 208–217.

Gupta, Sumati, Timothy J. Parnell, Andrew Butterfield, et al.. (2018). Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma. Molecular Cancer Therapeutics. 18(1). 185–195. 17 indexed citations

Shah, Manish A., Alexander Starodub, Sunil Sharma, et al.. (2018). Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clinical Cancer Research. 24(16). 3829–3837. 78 indexed citations

Andrade, Daniel, Jason Singer, Luke Maese, et al.. (2016). SUMOylation Regulates Growth Factor Independence 1 in Transcriptional Control and Hematopoiesis. Molecular and Cellular Biology. 36(10). 1438–1450. 15 indexed citations

10.

Agarwal, Neeraj, Jordan P. McPherson, Sumati Gupta, et al.. (2015). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemotherapy and Pharmacology. 77(2). 299–308. 10 indexed citations

11.

Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(5). 1142–1154. 155 indexed citations

12.

Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. Molecular Cancer Therapeutics. 13(10). 2315–2327. 112 indexed citations

13.

Sankar, Savita, Emily R. Theisen, Jared Bearss, et al.. (2014). Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth. Clinical Cancer Research. 20(17). 4584–4597. 125 indexed citations

14.

Maison‐Blanche, Pierre, Shaker R. Dakhil, Ari David Baron, et al.. (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(6). 1241–1252. 1 indexed citations

15.

Falchook, Gerald S., Razelle Kurzrock, Launce Gouw, et al.. (2014). Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. Investigational New Drugs. 32(6). 1181–1187. 31 indexed citations

16.

Theisen, Emily R., et al.. (2014). Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. BMC Cancer. 14(1). 752–752. 36 indexed citations

17.

Suttle, A. Benjamin, Kenneth F. Grossmann, Danièle Ouellet, et al.. (2014). Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib. The Journal of Clinical Pharmacology. 55(4). 392–400. 41 indexed citations

18.

Bendell, Johanna C., Michael S. Gordon, Herbert I. Hurwitz, et al.. (2013). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer. Clinical Cancer Research. 20(2). 480–489. 47 indexed citations

19.

Symanowski, James T., Nicholas J. Vogelzang, Leigh Zawel, et al.. (2009). A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL. Journal of Thoracic Oncology. 4(2). 149–160. 25 indexed citations

20.

Sharma, Sunil, et al.. (2006). Studies on Corneal Permeation and Oculo- Hypotensive Effect of Benazepril in Chronic and Acute Models of Glaucoma. TSpace. 5(2). 145–149. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact